Age-dependent humoral responses of children to mycobacterial antigens

Fairchok, Mary; Rouse, J. H.; Morris, Sheldon L.

doi:10.1128/cdli.2.4.443-447.1995

Cited by 29 publications

(7 citation statements)

References 39 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Costello et al reported that children from the United Kingdom and Southeast Asia with disseminated ATB disease had lower LAM-specific IgG serum-titers in comparison to individuals with localized ATB lesions ( 96 ). In agreement, the decrease in LAM IgG-titers from placentally transferred maternal IgGs until increased production of infant IgGs correlated with the peak incidence of disseminated ATB ( 96 – 98 ). Similarly, the absence of Abs binding to the mycobacterial 38 kDa Ag correlated with disseminated TB in children and TB-meningitis in adults ( 99 ).…”

Section: The Role Of Abs In the Host Defense Against Mtbsupporting

confidence: 71%

B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis

2021

View full text Add to dashboard Cite

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is still a major threat to mankind, urgently requiring improved vaccination and therapeutic strategies to reduce TB-disease burden. Most present vaccination strategies mainly aim to induce cell-mediated immunity (CMI), yet a series of independent studies has shown that B-cells and antibodies (Abs) may contribute significantly to reduce the mycobacterial burden. Although early studies using B-cell knock out animals did not support a major role for B-cells, more recent studies have provided new evidence that B-cells and Abs can contribute significantly to host defense against Mtb. B-cells and Abs exist in many different functional subsets, each equipped with unique functional properties. In this review, we will summarize current evidence on the contribution of B-cells and Abs to immunity toward Mtb, their potential utility as biomarkers, and their functional contribution to Mtb control.

show abstract

Section: The Role Of Abs In the Host Defense Against Mtbsupporting

confidence: 71%

B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis

2021

View full text Add to dashboard Cite

show abstract

“…There are reports that show cross-reactive antibodies generated by exposure to environmental mycobacteria or non-pathogenic enteric or pulmonary bacteria [ 56 , 57 ]. It has also been shown that the development of low level humoral immune responses to Mycobacterium avium sonic extracts and mycobacterial LAM in children correlates with increasing age, and by 18 years of age many individuals were sero-reactive to mycobacterial antigens [ 58 ].…”

Section: Discussionmentioning

confidence: 99%

IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals

et al. 2018

View full text Add to dashboard Cite

As part of a major project to investigate protective and diagnostic immune markers against tuberculosis (TB), we measured antibody isotype responses to Mycobacterium tuberculosis (Mtb) antigens (LAM, Rv2031, and HBHA) in cohorts of 149 pulmonary tuberculosis patients (PTBP), 148 household contacts (HHCs), and 68 community controls (CCs) in an endemic setting. ELISA was used to measure levels of IgA, IgG, and IgM from sera of cohorts at baseline, and at 6 and 12 months from entry. The results show that there were significant differences in IgA, IgG, and IgM responses to the different antigens and in the three cohorts. At baseline, the level of IgM against RV2031 and LAM did not vary between cohorts, but the levels of IgA and IgG against Rv2031 were significantly higher in PTB patients than HHCs and CCs, followed by HHCs, and the lowest in CCs. In patients, there was a significant variation in antibody responses before and after chemotherapy. The levels of IgA and IgG against HBHA, and IgA against Rv2031 decreased significantly and remained low, while IgA and IgG against LAM increased significantly and remained high following chemotherapy. However, the levels of IgM against Rv2031 and LAM increased at 6 months but decreased again at 12 months. IgM against HBHA did not show any significant variation before and after chemotherapy. Similarly, there were also significant variations in antibody responses in HHCs over time. Our results show that there are significant variations in IgA, IgG and IgM responses to the different antigens and in the three cohorts, implying that not all antibody isotype responses are markers of clinical TB. In addition, the current and previous studies consistently show that IgA and IgG against Rv2031 discriminate between clinical disease, Mtb-infected and non-infected individuals.

show abstract

“…24 Studies of antibody to Mycobacterium avium antigens in the non-BCG immunised persons in the United Kingdom and tuberculin skin test negative persons in the United States indicated that a high percentage of the population in northern regions has experienced asymptomatic infection with non-tuberculous mycobacteria. 25,26 This is not unexpected given the frequency of potable water colonisation described above.…”

Section: Heterologous Immunity and The Efficacy Of Bcg Boosters In Admentioning

confidence: 72%

Correcting the record on BCG before we license new vaccines against tuberculosis

Reyn

2017

J R Soc Med

View full text Add to dashboard Cite

Age-dependent humoral responses of children to mycobacterial antigens

Cited by 29 publications

References 39 publications

B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis

B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis

IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals

Correcting the record on BCG before we license new vaccines against tuberculosis

Contact Info

Product

Resources

About